Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2009-02-28
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In order to understand the effects of MDMA and role of serotonin in these effects, we will administer MDMA alone and in combination with the antidepressant citalopram (one trade name for this is Celexa). Citalopram decreases the ability of MDMA to release serotonin. Citalopram will therefore decrease any of MDMA's effects that are the result of serotonin release; we want to measure this.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of MDMA on Social and Emotional Processing
NCT01849419
Effects of MDMA-like Substances in Healthy Subjects
NCT04847206
Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)
NCT00886886
Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
NCT05379959
Effects of Drugs on Responses to Brain and Emotional Processes
NCT04053036
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
Placebo
drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
mdma
drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
MDMA and citalopram
MDMA 1.5 mg/kg and citalopram 20 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MDMA and citalopram
MDMA 1.5 mg/kg and citalopram 20 mg
Placebo
drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Experienced with MDMA
Exclusion Criteria
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
California Pacific Medical Center Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Mendelson, MD
Senior Scientist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CPMC Research Institute, St.Luke's Hospital
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
28.065-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.